Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4238-4245

  Knauf, Jeffrey A ^a   Ma, Xiaolan ^a   Smith, Eric P ^a   Zhang, Lei ^a   Mitsutake, Norisato ^a   Liao, Xiao Hui ^b   Refetoff, Samuel ^b   Nikiforov, Yuri E ^a   Fagin, James A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; LIOTHYRONINE; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN; THYROXINE; BRAF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GOITER; HUMAN; LIOTHYRONINE BLOOD LEVEL; MALE; MOUSE; NEWBORN; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL RATE; THYROID CELL; THYROID DISEASE; THYROID GLAND; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; GENETICS; METABOLISM; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PREGNANCY; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; THYROID TUMOR; TRANSGENE;

ANIMALS; BLOTTING, SOUTHERN; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUTATION; PREGNANCY; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TRANSGENES;

EID: 20144372793     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0047     Document Type: Article

References (44)

1. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89:202-17.
2. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183:249-56.
3. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002;963:116-21.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-7.
5. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5: 875-85.
6. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80.
7. Trovisco V, Vieira dC I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-51.
8. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
9. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-7.
10. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88:4393-7.
11. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
12. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625-7.
13. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45:818-21.
14. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 1994;19:474-80.
15. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93:53-62.
16. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
17. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
18. Garnett MJ, Marais R. Guilty as charged; B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.
19. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
20. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004.
21. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-12.
22. Castellone MD, Cirafici AM, De Vita G, et al. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene 2003;22:246-55.
23. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-63.
24. Nguyen LQ, Kopp P, Martinson F, Stanfield K, Roth SI, Jameson JL. A dominant negative CREB (cAMP response element-binding protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. Mol Endocrinol 2000;14: 1448-61.
25. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002; 32:1372-9.
26. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van SJ, Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid 19995;1265-71.
27. Robin NI, Hagen SR, Collaco F, Refetoff S, Selenkow HA. Serum tests for measurement of thyroid function. Hormones 1971;2:266-79.
28. Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 1999;18:3659-65.
29. Jhiang SM, Cho JY, Furminger TL, et al. Thyroid carcinomas in RET/PTC transgenic mice. Recent Results Cancer Res 1998;154:265-70.
30. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987;7:3365-70.
31. Missero C, Pirro MT, Di Lauro R. Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 2000;20:2783-93.
32. Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002;12:963-9.
33. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71-7.
34. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4.
35. Powell DJJ, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998;58:5523-8.
36. Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996;137:375-8.
37. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 2000;157: 671-7.
38. -/- mice. Oncogene 2001 May 31;20:3235-46.
39. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985;83:135-58.
40. Moeller LC, Kimura S, Kusakabe T, Liao XH, Van SJ, Refetoff S. Hypothyroidism in thyroid transcription factor 1 haploinsufficiency is caused by reduced expression of the thyroid-stimulating hormone receptor. Mol Endocrinol 2003;17:2295-302.
41. Kimura T, Van KA, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56.
42. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000;6:469-76.
43. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502.
44. Boelaert K, Horacek Y, Daykin J, Sheppard M, Franklyn J. Gender, age, goitre type and serum TSH level predict thyroid neoplasia in 1500 patients with thyroid enlargement investigated by FNAC. 23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies, March 22-24 2004; p. 757(Abstract).